Skip to main content
Erschienen in: PharmacoEconomics 5/2000

01.11.2000 | Review Article

Health-Related Quality-of-Life Measurement in Hypertension

A Review of Randomised Controlled Drug Trials

verfasst von: Isabelle Côté, Dr Jean-Pierre Grégoire, Jocelyne Moisan

Erschienen in: PharmacoEconomics | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

In hypertension, tolerability of drug treatment is important because individuals may see the use of antihypertensive medications as more troubling than their seemingly symptom less disease. This may result in noncompliance and ineffectual long term treatment. In the past 15 years, new antihypertensive medications have been marketed on the basis of the advantages they offer with regard to adverse effects and the unavoidable impact of such adverse effects on a person’s quality of life. When related to health, quality of life refers to the physical, psychological and social dimensions of health that are influenced by a person’s experiences, beliefs, expectations and perceptions. To measure this concept, many instruments, either generic or specific, may be used. The purpose of this study is to describe, by way of a critical review of the literature, the instruments that are most often used in the measurement of health-related quality of life (HR-QOL) in people using antihypertensive drug treatments.
We carried out a search of the literature published in English in the period January 1966 to July 2000, looking for randomised controlled trials of antihypertensive drugs. Using the Medline database, we included 77 papers in our review.
Our main finding suggests that HR-QOL changes associated with antihypertensive treatment are measured with many different instruments. In almost all studies, at least 1 instrument specific to a health dimension was used, whereas not many used a generic instrument only. The most commonly measured HR-QOL dimensions were cognitive function, symptomatic well-being, sexual function, psychological well-being, sleep dysfunction, social participation and general health perception. Since the choice of dimensions to measure depends not only on the disease but also on the drug, this review adds further evidence that a generic instrument as well as a preference measurement should be added to a specific instrument.
Literatur
1.
Zurück zum Zitat Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64PubMed Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64PubMed
2.
Zurück zum Zitat Rice S, Miller MD. Developing a model for the study of quality of life in elderly patients with chronic disease: use of hypertension as an example. South Med J 1990; 83: 941–6PubMed Rice S, Miller MD. Developing a model for the study of quality of life in elderly patients with chronic disease: use of hypertension as an example. South Med J 1990; 83: 941–6PubMed
3.
Zurück zum Zitat Lindstrom B. Quality of life: a model for evaluating health for all. Conceptual considerations and policy implications. Soz Praventivmed 1992; 37: 301–6PubMed Lindstrom B. Quality of life: a model for evaluating health for all. Conceptual considerations and policy implications. Soz Praventivmed 1992; 37: 301–6PubMed
4.
Zurück zum Zitat Hume AL. Applying quality of life data in practice: considerations for antihypertensive therapy. J Fam Pract 1989; 28: 403–7PubMed Hume AL. Applying quality of life data in practice: considerations for antihypertensive therapy. J Fam Pract 1989; 28: 403–7PubMed
5.
Zurück zum Zitat Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–40PubMed Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–40PubMed
6.
Zurück zum Zitat Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1998 Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1998
7.
Zurück zum Zitat Ware Jr JE, Sherbourne CD. The MOS 36-items short-form health survey (SF-36): I: conceptual framework and item selection. Med Care 1992; 30: 473–83PubMed Ware Jr JE, Sherbourne CD. The MOS 36-items short-form health survey (SF-36): I: conceptual framework and item selection. Med Care 1992; 30: 473–83PubMed
8.
Zurück zum Zitat Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 29: 787–805 Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 29: 787–805
9.
Zurück zum Zitat Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217–32 Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217–32
10.
Zurück zum Zitat Bakker C, van der Linden S. Health related utility measurement: an introduction. J Rheumatol 1995; 22: 1197–9PubMed Bakker C, van der Linden S. Health related utility measurement: an introduction. J Rheumatol 1995; 22: 1197–9PubMed
11.
Zurück zum Zitat Froberg DG, Kane RL. Methodology for measuring health-state preferences — II: scaling methods. J Clin Epidemiol 1989; 42: 459–71PubMed Froberg DG, Kane RL. Methodology for measuring health-state preferences — II: scaling methods. J Clin Epidemiol 1989; 42: 459–71PubMed
12.
Zurück zum Zitat Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000; 17 (2): 151–65PubMed Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000; 17 (2): 151–65PubMed
13.
Zurück zum Zitat Hurst NP,Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EUROQOL (EQ-5D). Br J Rheumatol 1997; 36: 551–9 Hurst NP,Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EUROQOL (EQ-5D). Br J Rheumatol 1997; 36: 551–9
14.
Zurück zum Zitat Office Canadien de Coordination de l’Évaluation des Technologies de la Sant‚. Lignes directrices pour l’‚valuation ‚conomique des produits pharmaceutiques: Canada. 1Šre ed. Ottawa: OCCETS, 1994 Office Canadien de Coordination de l’Évaluation des Technologies de la Sant‚. Lignes directrices pour l’‚valuation ‚conomique des produits pharmaceutiques: Canada. 1Šre ed. Ottawa: OCCETS, 1994
15.
Zurück zum Zitat Leidy N, Rentz A, Zyczynski T. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure. Pharmacoeconomics 1999; 15 (1): 19–46PubMed Leidy N, Rentz A, Zyczynski T. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure. Pharmacoeconomics 1999; 15 (1): 19–46PubMed
16.
Zurück zum Zitat de Hoon JN, Vanmolkot FH, van de Ven LL, et al. Quality of life comparison between bisoprolol and nifedipine retard in hypertension. Cardiovasc Drugs Ther 1997; 11: 465–71PubMed de Hoon JN, Vanmolkot FH, van de Ven LL, et al. Quality of life comparison between bisoprolol and nifedipine retard in hypertension. Cardiovasc Drugs Ther 1997; 11: 465–71PubMed
17.
Zurück zum Zitat Grimm Jr RH, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study. Arch Intern Med 1997; 157: 638–48PubMed Grimm Jr RH, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study. Arch Intern Med 1997; 157: 638–48PubMed
18.
Zurück zum Zitat Grimm Jr RH, Flack JM, Schoenberger JA, et al. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. Am J Hypertens 1996; 9: 445–54PubMed Grimm Jr RH, Flack JM, Schoenberger JA, et al. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. Am J Hypertens 1996; 9: 445–54PubMed
19.
Zurück zum Zitat Kusek JW, Lee JY, Smith DE, et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17: 40S-6S Kusek JW, Lee JY, Smith DE, et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17: 40S-6S
20.
Zurück zum Zitat Lewis CE, Grandits A, Flack J, et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med 1996; 156: 377–85PubMed Lewis CE, Grandits A, Flack J, et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med 1996; 156: 377–85PubMed
21.
Zurück zum Zitat Ostergren J, Storstein L, Karlberg BE, et al. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996; 5: 41–9PubMed Ostergren J, Storstein L, Karlberg BE, et al. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996; 5: 41–9PubMed
22.
Zurück zum Zitat Boissel JP, Collet JP, Lion L, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. J Hypertens 1995; 13: 1059–67PubMed Boissel JP, Collet JP, Lion L, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. J Hypertens 1995; 13: 1059–67PubMed
23.
Zurück zum Zitat Perez-Stable EJ, Coates TJ, Baron RB, et al. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. J Gen Intern Med 1995; 10: 419–28PubMed Perez-Stable EJ, Coates TJ, Baron RB, et al. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. J Gen Intern Med 1995; 10: 419–28PubMed
24.
Zurück zum Zitat Yajnik VH, Vatsraj DJ, Acharya HK, et al. Ramipril vs captopril in mild to moderate hypertension. J Assoc Physicians India 1994; 42: 120–3PubMed Yajnik VH, Vatsraj DJ, Acharya HK, et al. Ramipril vs captopril in mild to moderate hypertension. J Assoc Physicians India 1994; 42: 120–3PubMed
25.
Zurück zum Zitat Bursztyn M, Ghanem J, Kobrin I, et al. Comparison of verapamil and captopril in elderly hypertensive subjects: results of a randomized, double-blind, crossover study. J Cardiovasc Pharmacol 1993; 21: 84–8PubMed Bursztyn M, Ghanem J, Kobrin I, et al. Comparison of verapamil and captopril in elderly hypertensive subjects: results of a randomized, double-blind, crossover study. J Cardiovasc Pharmacol 1993; 21: 84–8PubMed
26.
Zurück zum Zitat McCorvey Jr E, Wright Jr JT, Culbert JP, et al. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clin Pharm 1993; 12: 300–5PubMed McCorvey Jr E, Wright Jr JT, Culbert JP, et al. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clin Pharm 1993; 12: 300–5PubMed
27.
Zurück zum Zitat Neaton JD, Grimm Jr RH, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713–24PubMed Neaton JD, Grimm Jr RH, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713–24PubMed
28.
Zurück zum Zitat Treatment of Mild Hypertension Study Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo- controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1991; 151: 1413–23 Treatment of Mild Hypertension Study Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo- controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1991; 151: 1413–23
29.
Zurück zum Zitat Weir MR, Josselson J, Ekelund LG, et al. Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J Hum Hypertens 1991; 5: 205–13PubMed Weir MR, Josselson J, Ekelund LG, et al. Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J Hum Hypertens 1991; 5: 205–13PubMed
30.
Zurück zum Zitat Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302PubMed Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302PubMed
31.
Zurück zum Zitat Cleophas TJ, van der Mey N, van der Meulen J, et al. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Int J Clin Pharmacol Ther 1996; 34: 312–7PubMed Cleophas TJ, van der Mey N, van der Meulen J, et al. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Int J Clin Pharmacol Ther 1996; 34: 312–7PubMed
32.
Zurück zum Zitat Yodfat Y, Bar-On D, Amir M, et al. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. J Hum Hypertens 1996; 10: 117–22PubMed Yodfat Y, Bar-On D, Amir M, et al. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. J Hum Hypertens 1996; 10: 117–22PubMed
33.
Zurück zum Zitat Chang SW, Fine R, Siegel D, et al. The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991; 151: 2402–8PubMed Chang SW, Fine R, Siegel D, et al. The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991; 151: 2402–8PubMed
34.
Zurück zum Zitat Wiklund I, Halling K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997; 6: 357–64PubMed Wiklund I, Halling K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997; 6: 357–64PubMed
35.
Zurück zum Zitat Paran E, Anson O, Neumann L. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens 1996; 9: 1206–13PubMed Paran E, Anson O, Neumann L. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens 1996; 9: 1206–13PubMed
36.
Zurück zum Zitat Neutel JM, Smith DH, Lefkowitz MP, et al. Hypertension in the elderly: 24 h ambulatory blood pressure results from a placebo- controlled trial. J Hum Hypertens 1995; 9: 723–7PubMed Neutel JM, Smith DH, Lefkowitz MP, et al. Hypertension in the elderly: 24 h ambulatory blood pressure results from a placebo- controlled trial. J Hum Hypertens 1995; 9: 723–7PubMed
37.
Zurück zum Zitat Omvik P, Herland OB, Thaulow E, et al. Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension. J Hum Hypertens 1995; 9 Suppl. 1: S17–24 Omvik P, Herland OB, Thaulow E, et al. Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension. J Hum Hypertens 1995; 9 Suppl. 1: S17–24
38.
Zurück zum Zitat Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994; 154: 2154–60PubMed Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994; 154: 2154–60PubMed
39.
Zurück zum Zitat Croog SH, EliasMF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994; 7: 329–39PubMed Croog SH, EliasMF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994; 7: 329–39PubMed
40.
Zurück zum Zitat Walle PO, Westergren G, Dimenas E, et al. Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. J Clin Pharmacol 1994; 34: 742–7PubMed Walle PO, Westergren G, Dimenas E, et al. Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. J Clin Pharmacol 1994; 34: 742–7PubMed
41.
Zurück zum Zitat Ferrara LA, Di Marino L, Russo O, et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension 1993; 21: 97–104PubMed Ferrara LA, Di Marino L, Russo O, et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension 1993; 21: 97–104PubMed
42.
Zurück zum Zitat Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. N Engl J Med 1993; 328: 907–13PubMed Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. N Engl J Med 1993; 328: 907–13PubMed
43.
Zurück zum Zitat Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: impact of responder, survey environment, and questionnaire structure. J Cardiovasc Pharmacol 1993; 21 Suppl. 2: S18–25 Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: impact of responder, survey environment, and questionnaire structure. J Cardiovasc Pharmacol 1993; 21 Suppl. 2: S18–25
44.
Zurück zum Zitat Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments: cilazapril, atenolol, nifedipine. Hypertension 1992; 19: 499–507PubMed Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments: cilazapril, atenolol, nifedipine. Hypertension 1992; 19: 499–507PubMed
45.
Zurück zum Zitat Fletcher AE, Battersby C, Adnitt P, et al. Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group. J Cardiovasc Pharmacol 1992; 20: 108–14PubMed Fletcher AE, Battersby C, Adnitt P, et al. Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group. J Cardiovasc Pharmacol 1992; 20: 108–14PubMed
46.
Zurück zum Zitat Kostis JB, Rosen RC, Brondolo E, et al. Superiority of non-pharmacologic therapy compared to propranolol and placebo in men with mild hypertension: a randomized, prospective trial. AmHeart J 1992; 123: 466–74 Kostis JB, Rosen RC, Brondolo E, et al. Superiority of non-pharmacologic therapy compared to propranolol and placebo in men with mild hypertension: a randomized, prospective trial. AmHeart J 1992; 123: 466–74
47.
Zurück zum Zitat Palmer AJ, Fletcher AE, Rudge PJ, et al. Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. J Hypertens 1992; 10: 1409–16PubMed Palmer AJ, Fletcher AE, Rudge PJ, et al. Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. J Hypertens 1992; 10: 1409–16PubMed
48.
Zurück zum Zitat Ameling EH, de Korte DF, Man in’tVeld A. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991; 18: 752–60PubMed Ameling EH, de Korte DF, Man in’tVeld A. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991; 18: 752–60PubMed
49.
Zurück zum Zitat Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med 1991; 151: 1817–23PubMed Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med 1991; 151: 1817–23PubMed
50.
Zurück zum Zitat Dimenas E, Wallander MA, Svardsudd K, et al. Aspects of quality of life on treatment with felodipine. Eur J Clin Pharmacol 1991; 40: 141–7PubMed Dimenas E, Wallander MA, Svardsudd K, et al. Aspects of quality of life on treatment with felodipine. Eur J Clin Pharmacol 1991; 40: 141–7PubMed
51.
Zurück zum Zitat Fletcher AE, Beevers DG, Dollery CT, et al. The effects of two centrally-acting anti-hypertensive drugs on the quality of life. Eur J Clin Pharmacol 1991; 41: 397–400PubMed Fletcher AE, Beevers DG, Dollery CT, et al. The effects of two centrally-acting anti-hypertensive drugs on the quality of life. Eur J Clin Pharmacol 1991; 41: 397–400PubMed
52.
Zurück zum Zitat Frimodt-Moeller J, Poulsen DL, Kornerup HJ, et al. Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. J Hum Hypertens 1991; 5: 215–21PubMed Frimodt-Moeller J, Poulsen DL, Kornerup HJ, et al. Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. J Hum Hypertens 1991; 5: 215–21PubMed
53.
Zurück zum Zitat Sundar S, Rajan AG, Somani PN, et al. The effects of antihypertensive agents on the quality of life in Indian hypertensives. Acta Cardiol 1991; 46: 227–35PubMed Sundar S, Rajan AG, Somani PN, et al. The effects of antihypertensive agents on the quality of life in Indian hypertensives. Acta Cardiol 1991; 46: 227–35PubMed
54.
Zurück zum Zitat Testa MA, Hollenberg NK, Anderson RB, et al. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991; 4: 363–73PubMed Testa MA, Hollenberg NK, Anderson RB, et al. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991; 4: 363–73PubMed
55.
Zurück zum Zitat Blumenthal JA, Ekelund LG, Emery CF. Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. Clin Pharmacol Ther 1990; 48: 447–54PubMed Blumenthal JA, Ekelund LG, Emery CF. Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. Clin Pharmacol Ther 1990; 48: 447–54PubMed
56.
Zurück zum Zitat Croog SH, Kong BW, Levine S, et al. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black hypertension quality of life multicenter trial group. Arch Intern Med 1990; 150: 1733–41PubMed Croog SH, Kong BW, Levine S, et al. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black hypertension quality of life multicenter trial group. Arch Intern Med 1990; 150: 1733–41PubMed
57.
Zurück zum Zitat Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: a randomized double-blind controlled trial of captopril and atenolol. J Hypertens 1990; 8: 463–6PubMed Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: a randomized double-blind controlled trial of captopril and atenolol. J Hypertens 1990; 8: 463–6PubMed
58.
Zurück zum Zitat Glik DC, Steadman MS, Michels PJ, et al. Antihypertensive regimen and quality of life in a disadvantaged population [discussion 50–2]. J Fam Pract 1990; 30: 143–9PubMed Glik DC, Steadman MS, Michels PJ, et al. Antihypertensive regimen and quality of life in a disadvantaged population [discussion 50–2]. J Fam Pract 1990; 30: 143–9PubMed
59.
Zurück zum Zitat Palmer A, Fletcher A, Hamilton G, et al. A comparison of verapamil and nifedipine on quality of life. Br J Clin Pharmacol 1990; 30: 365–70PubMed Palmer A, Fletcher A, Hamilton G, et al. A comparison of verapamil and nifedipine on quality of life. Br J Clin Pharmacol 1990; 30: 365–70PubMed
60.
Zurück zum Zitat Steiner SS, Friedhoff AJ, Wilson BL, et al. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990; 4: 217–25PubMed Steiner SS, Friedhoff AJ, Wilson BL, et al. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990; 4: 217–25PubMed
61.
Zurück zum Zitat Fletcher AE, Chester PC, Hawkins CM, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989; 3: 125–30PubMed Fletcher AE, Chester PC, Hawkins CM, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989; 3: 125–30PubMed
62.
Zurück zum Zitat Herrick AL, Waller PC, Berkin KE, et al. Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med 1989; 86: 421–6PubMed Herrick AL, Waller PC, Berkin KE, et al. Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med 1989; 86: 421–6PubMed
63.
Zurück zum Zitat Blumenthal JA, Madden DJ, Krantz DS, et al. Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension. Clin Pharmacol Ther 1988; 43: 429–35PubMed Blumenthal JA, Madden DJ, Krantz DS, et al. Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension. Clin Pharmacol Ther 1988; 43: 429–35PubMed
64.
Zurück zum Zitat Croog SH, Levine S, Sudilovsky A, et al. Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. Arch Intern Med 1988; 148: 788–94PubMed Croog SH, Levine S, Sudilovsky A, et al. Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. Arch Intern Med 1988; 148: 788–94PubMed
65.
Zurück zum Zitat Dahlof C, Almkvist G, Dimenas E, et al. No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR. Ann Clin Res 1988; 20 Suppl. 48: 42–50PubMed Dahlof C, Almkvist G, Dimenas E, et al. No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR. Ann Clin Res 1988; 20 Suppl. 48: 42–50PubMed
66.
Zurück zum Zitat Zachariah PK, Brobyn R, Kann J, et al. Comparison of quality of life on nitrendipine and propranolol. J Cardiovasc Pharmacol 1988; 12 Suppl. 4: S29–35 Zachariah PK, Brobyn R, Kann J, et al. Comparison of quality of life on nitrendipine and propranolol. J Cardiovasc Pharmacol 1988; 12 Suppl. 4: S29–35
67.
Zurück zum Zitat Levine S, Croog SH, Sudilovsky A, et al. Effects of antihypertensive medications on vitality and well-being. J Fam Pract 1987; 25: 357–63PubMed Levine S, Croog SH, Sudilovsky A, et al. Effects of antihypertensive medications on vitality and well-being. J Fam Pract 1987; 25: 357–63PubMed
68.
Zurück zum Zitat Otten H, Schmeider R, Ruddel H. Disparate effects of initial antihypertensive therapy on well-being. J Hypertens 1987; Suppl. 5: S37–40 Otten H, Schmeider R, Ruddel H. Disparate effects of initial antihypertensive therapy on well-being. J Hypertens 1987; Suppl. 5: S37–40
69.
Zurück zum Zitat Hill JF, Bulpitt CJ, Fletcher AE. Angiotensin converting enzyme inhibitors and quality of life: the European trial. J Hypertens 1985; Suppl. 3: S91–4 Hill JF, Bulpitt CJ, Fletcher AE. Angiotensin converting enzyme inhibitors and quality of life: the European trial. J Hypertens 1985; Suppl. 3: S91–4
70.
Zurück zum Zitat Chan P, Lin CN, Tomlinson B, et al. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997; 10: 743–9PubMed Chan P, Lin CN, Tomlinson B, et al. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997; 10: 743–9PubMed
71.
Zurück zum Zitat Dahlof B, Lindholm LH, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. J Hypertens 1997; 15: 1327–35PubMed Dahlof B, Lindholm LH, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. J Hypertens 1997; 15: 1327–35PubMed
72.
Zurück zum Zitat Rosenthal J, Bahrmann H, Benkert K, et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Cardiology 1996; 87: 409–14PubMed Rosenthal J, Bahrmann H, Benkert K, et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Cardiology 1996; 87: 409–14PubMed
73.
Zurück zum Zitat Van Ree JW, Van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. J Hum Hypertens 1996; 10: 613–8PubMed Van Ree JW, Van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. J Hum Hypertens 1996; 10: 613–8PubMed
74.
Zurück zum Zitat Levine JH, Ferdinand KC, Cargo P, et al. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995; 8: 494–9PubMed Levine JH, Ferdinand KC, Cargo P, et al. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995; 8: 494–9PubMed
75.
Zurück zum Zitat Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130: 359–66PubMed Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130: 359–66PubMed
76.
Zurück zum Zitat Perry Jr HM, Hall WD, Benz JR, et al. Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. Am J Med 1994; 96: 77–86PubMed Perry Jr HM, Hall WD, Benz JR, et al. Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. Am J Med 1994; 96: 77–86PubMed
77.
Zurück zum Zitat Van Bortel LM, Breed JG, Joosten J, et al. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856–62PubMed Van Bortel LM, Breed JG, Joosten J, et al. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856–62PubMed
78.
Zurück zum Zitat Dahlof C, Hedner T, Thulin T, et al. Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being. The Swedish Diltiazem-Metoprolol Multi-Centre Study Group. Eur J Clin Pharmacol 1991; 40: 453–60PubMed Dahlof C, Hedner T, Thulin T, et al. Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being. The Swedish Diltiazem-Metoprolol Multi-Centre Study Group. Eur J Clin Pharmacol 1991; 40: 453–60PubMed
79.
Zurück zum Zitat Fagher B, Katzman P, Hulthen UL, et al. Antihypertensive efficacy and tolerability of enalapril and slow- release verapamil in essential hypertension: a double-blind, cross-over study. J Intern Med 1991; 230: 219–26PubMed Fagher B, Katzman P, Hulthen UL, et al. Antihypertensive efficacy and tolerability of enalapril and slow- release verapamil in essential hypertension: a double-blind, cross-over study. J Intern Med 1991; 230: 219–26PubMed
80.
Zurück zum Zitat Hunter Hypertension Research Group. Well-being and its measurement in hypertension. Arandomized, double-blind cross-over comparison of 5 mg clopamide with 25 mg hydrochlorothiazide. Clin Exp Hypertens [A] 1991; 13: 189–95 Hunter Hypertension Research Group. Well-being and its measurement in hypertension. Arandomized, double-blind cross-over comparison of 5 mg clopamide with 25 mg hydrochlorothiazide. Clin Exp Hypertens [A] 1991; 13: 189–95
81.
Zurück zum Zitat Jern S, Hansson L, Scherst‚n B, et al. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. J Cardiovasc Pharmacol 1991; 18: S7-S8 Jern S, Hansson L, Scherst‚n B, et al. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. J Cardiovasc Pharmacol 1991; 18: S7-S8
82.
Zurück zum Zitat Os I, Bratland B, Dahlof B, et al. Lisinopril and nifedipine in essential hypertension: a Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 1991; 9: S382-S3 Os I, Bratland B, Dahlof B, et al. Lisinopril and nifedipine in essential hypertension: a Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 1991; 9: S382-S3
83.
Zurück zum Zitat Chatellier G, Sassano P, Amiot AM, et al. Efficacy and influence on quality of life of enalapril as a first step treatment of hypertension. Clin Exp Hypertens [A] 1987; 9: 513–9 Chatellier G, Sassano P, Amiot AM, et al. Efficacy and influence on quality of life of enalapril as a first step treatment of hypertension. Clin Exp Hypertens [A] 1987; 9: 513–9
84.
Zurück zum Zitat Tanser PH, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. Am J Hypertens 2000; 13: 214–8PubMed Tanser PH, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. Am J Hypertens 2000; 13: 214–8PubMed
85.
Zurück zum Zitat Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12: 1130–4PubMed Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12: 1130–4PubMed
86.
Zurück zum Zitat Anderson RB, Hollenberg NK, Williams GH. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med 1999; 159: 693–700PubMed Anderson RB, Hollenberg NK, Williams GH. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med 1999; 159: 693–700PubMed
87.
Zurück zum Zitat Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension [see comments]. Am J Med 2000; 108: 359–65PubMed Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension [see comments]. Am J Med 2000; 108: 359–65PubMed
88.
Zurück zum Zitat Warner Jr JG, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999; 33: 1567–72PubMed Warner Jr JG, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999; 33: 1567–72PubMed
89.
Zurück zum Zitat Vanmolkot FH, de Hoon JN, van de Ven LL, et al. Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. J Hum Hypertens 1999; 13: 559–63PubMed Vanmolkot FH, de Hoon JN, van de Ven LL, et al. Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. J Hum Hypertens 1999; 13: 559–63PubMed
90.
Zurück zum Zitat Ogihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res 2000; 23: 33–7PubMed Ogihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res 2000; 23: 33–7PubMed
91.
Zurück zum Zitat Bulpitt CJ, Connor M, Schulte M, et al. Bisoprolol and nifedipine retard in elderly hypertensive patients: effect on quality of life. J Hum Hypertens 2000; 14: 205–12PubMed Bulpitt CJ, Connor M, Schulte M, et al. Bisoprolol and nifedipine retard in elderly hypertensive patients: effect on quality of life. J Hum Hypertens 2000; 14: 205–12PubMed
92.
Zurück zum Zitat Hatton DC, Haynes RB, Oparil S, et al. Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared diet. Am J Clin Nutr 1996; 64: 935–43PubMed Hatton DC, Haynes RB, Oparil S, et al. Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared diet. Am J Clin Nutr 1996; 64: 935–43PubMed
93.
Zurück zum Zitat Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411–28PubMed Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411–28PubMed
94.
Zurück zum Zitat Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 407–13PubMed Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 407–13PubMed
95.
Zurück zum Zitat Jenkinson C, Fitzpatrick R, Peto V. Health-related quality-of-life measurement in patients with Parkinson’s disease. Pharmacoeconomics 1999; 15: 157–65PubMed Jenkinson C, Fitzpatrick R, Peto V. Health-related quality-of-life measurement in patients with Parkinson’s disease. Pharmacoeconomics 1999; 15: 157–65PubMed
96.
Zurück zum Zitat Walker M, Salek S, Bayer A. A review of quality of life in Alzheimer’s disease. Pharmacoeconomics 1998; 14: 499–530PubMed Walker M, Salek S, Bayer A. A review of quality of life in Alzheimer’s disease. Pharmacoeconomics 1998; 14: 499–530PubMed
97.
Zurück zum Zitat Juniper J. Quality-of-life considerations in the treatment of asthma. Pharmacoeconomics 1995; 8: 123–38PubMed Juniper J. Quality-of-life considerations in the treatment of asthma. Pharmacoeconomics 1995; 8: 123–38PubMed
98.
Zurück zum Zitat Tullis E, Guyatt G. Quality of life in cystic fibrosis. Pharmacoeconomics 1995; 8: 23–33PubMed Tullis E, Guyatt G. Quality of life in cystic fibrosis. Pharmacoeconomics 1995; 8: 23–33PubMed
99.
Zurück zum Zitat de Boer J, van Dam F, Sprangers M. Health-related quality-of-life evaluation in HIV-infected patients. Pharmacoeconomics 1995; 8: 291–304PubMed de Boer J, van Dam F, Sprangers M. Health-related quality-of-life evaluation in HIV-infected patients. Pharmacoeconomics 1995; 8: 291–304PubMed
100.
Zurück zum Zitat Jacobs P, Bachynsky J, Baladi J. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8 (3): 182–9PubMed Jacobs P, Bachynsky J, Baladi J. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8 (3): 182–9PubMed
101.
Zurück zum Zitat Chwalow AJ. Cross-cultural validation of existing quality of life scales. Patient Educ Couns 1995; 26: 313–8PubMed Chwalow AJ. Cross-cultural validation of existing quality of life scales. Patient Educ Couns 1995; 26: 313–8PubMed
102.
Zurück zum Zitat Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17 (1): 13–35PubMed Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17 (1): 13–35PubMed
103.
Zurück zum Zitat Guadagnoli E, Nordberg P, Mor V. Social interaction tests and scales. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 97–105 Guadagnoli E, Nordberg P, Mor V. Social interaction tests and scales. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 97–105
104.
Zurück zum Zitat Anderson R, Aaronson N, LeplŠgeA, et al. International use and application of generic health-related quality of life instruments. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 613–32 Anderson R, Aaronson N, LeplŠgeA, et al. International use and application of generic health-related quality of life instruments. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 613–32
Metadaten
Titel
Health-Related Quality-of-Life Measurement in Hypertension
A Review of Randomised Controlled Drug Trials
verfasst von
Isabelle Côté
Dr Jean-Pierre Grégoire
Jocelyne Moisan
Publikationsdatum
01.11.2000
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 5/2000
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200018050-00003

Weitere Artikel der Ausgabe 5/2000

PharmacoEconomics 5/2000 Zur Ausgabe